Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Niagen Bioscience, Inc. (NAGE)

2.4000 +0.0700 (+3.00%)
At close: November 2 at 4:00:00 PM EST
2.3643 -0.0357 (-1.49%)
After hours: November 2 at 4:08:09 PM EST
Trade NAGE on Coinbase
NAGE Q3 2026 earnings call
November 4, 2026 at 4:30 PM EST

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Frank Louis Jaksch Jr.
Co-Founder & Chairman 70k -- 1968
Mr. Robert N. Fried
CEO & Director 1.21M 182.67k 1960
Mr. Ozan Pamir C.F.A.
CFO & Principal Accounting Officer 648.24k -- 1992
Mr. Carlos Lopez
Senior VP & General Counsel 480.03k -- 1981
Dr. Andrew Shao Ph.D.
Senior Vice President of Global Regulatory & Scientific Affairs -- -- --
Ms. Michiko Kelley
Chief Marketing Officer -- -- --
Ms. Chu Yan
Managing Director of Asia Pacific -- -- --
Kendall Knysch
Head of Media Relations & Partnerships -- -- --
Mr. James Lee
Controller 286.49k -- 1976
Wesley Yu
Vice President of Finance -- -- --

Niagen Bioscience, Inc.

10900 Wilshire Blvd
Suite 600
Los Angeles, CA 90024
United States
310 388 6706 https://www.niagenbioscience.com
Sector: 
Consumer Defensive
Industry: 
Packaged Foods
Full Time Employees: 
117

Description

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Corporate Governance

Niagen Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 4, 2026 at 9:00 PM UTC

Niagen Bioscience, Inc. Earnings Date

Recent Events

August 4, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

June 29, 2026 at 12:00 AM UTC

S-3: Offering Registrations

May 6, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 29, 2026 at 12:00 AM UTC

ARS: Annual Report to Shareholders

March 19, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 4, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 26, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 22, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 6, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 4, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: